Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Z S PavleticA Kessinger

Abstract

To compare hematopoietic recovery, duration of hospitalization, and 100-day survival in patients who received allogeneic-blood stem cells (BSC) or conventional allogeneic bone marrow transplantation (BMT). From December 1994 to August 1995, 21 patients participated in a phase II study of allogeneic BSC transplantation. Cells mobilized with granulocyte colony-stimulating factor (G-CSF; 5 micrograms/kg/ d) were collected from human leukocyte antigen (HLA)-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. G-CSF (10 micrograms/kg/d) was administered posttransplant. The outcomes were compared with 22 identically treated historical patients who received allogeneic BMT. The median infused CD34+ cell and granulocyte-macrophage colony-forming unit (CFU-GM) content were 7.73 x 10(4)/kg and 41.6 x 10(4)/kg, respectively. The median time to a neutrophil count greater than 500/ microL was 11 days after BSC and 16.5 days after BMT (P = .0003). A trend toward faster platelet and RBC recovery after BSC was observed. BSC patients received fewer platelet transfusions: 10 versus 19 (P = .015). The median length of hospitalization was shorter after BSC transplantation...Continue Reading

Citations

Apr 4, 2000·Bone Marrow Transplantation·Z S PavleticM R Bishop
Feb 10, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Marcia GrantStephen Forman
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H OzerUNKNOWN American Society of Clinical Oncology
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C CutlerJ H Antin
Jul 30, 2003·Cancer Nursing·Eileen Danaher Hacker, Carol Estwing Ferrans
Mar 30, 2005·American Journal of Hematology·Steven Z PavleticAnne Kessinger
Sep 27, 2003·British Journal of Haematology·Antonio PagliucaUNKNOWN Haemato-Oncology Task Force of the British Committee for Standards in Haematology
Oct 31, 2000·Current Opinion in Hematology·A BacigalupoM T Van Lint
Feb 27, 2001·Bone Marrow Transplantation·J M CroopR Abonour
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A BrownJ F DiPersio
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M EngelhardtJ Finke
Apr 14, 2006·Expert Opinion on Biological Therapy·Michael Y ShapiraShimon Slavin
Nov 6, 2009·Oncology Nursing Forum·Margaret BevansKim Schmit-Pokorny
Nov 18, 2008·Bone Marrow Transplantation·R M SalibaM de Lima
Jan 11, 2014·Current Allergy and Asthma Reports·Jaime M BrozowskiTeresa K Tarrant
Feb 15, 2001·Journal of Hematotherapy & Stem Cell Research·J G SharpS S Joshi
Apr 13, 2000·Cancer Control : Journal of the Moffitt Cancer Center·S J Noga, P V O'Donnell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.